MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
DarioHealth Corp. Book Value 2011-2025 | DRIO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value DarioHealth Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.4 M | 119 M | 101 M | 28.2 M | 18.9 M | 8.92 M | 3.94 M | -6.54 M | 777 K | -2.54 M | -86.4 K | -1.07 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 119 M | -6.54 M | 30.6 M |
Quarterly Book Value DarioHealth Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 118 M | 108 M | 116 M | 119 M | 110 M | 122 M | 137 M | 96.4 M | 107 M | 117 M | 108 M | 119 M | 126 M | 137 M | 127 M | 101 M | 117 M | 131 M | 124 M | 35.4 M | 35.4 M | 35.4 M | 35.4 M | 24.6 M | 24.6 M | 24.6 M | 24.6 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M | 6.96 M | 6.96 M | 6.96 M | 6.96 M | 3.87 M | 3.87 M | 3.87 M | 3.87 M | 5.08 M | 5.08 M | 5.08 M | 5.08 M | 3.08 M | 3.08 M | 3.08 M | 3.08 M | 4.12 M | 4.12 M | 4.12 M | 4.12 M | 2.32 M | 2.32 M | 2.32 M | 2.32 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 137 M | 2.32 M | 48 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brainsway Ltd.
BWAY
|
75.7 M | $ 17.13 | 1.66 % | $ 99.4 M |  Israel |
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DexCom
DXCM
|
2.07 B | $ 66.06 | -1.34 % | $ 25.5 B |  USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 101.57 | 0.07 % | $ 18.8 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.0 | 1.59 % | $ 172 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
35.4 M | $ 1.56 | -3.7 % | $ 1.98 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
456 M | $ 38.95 | 0.82 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 227.29 | 0.42 % | $ 166 B | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 26.94 | -0.74 % | $ 815 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Mettler-Toledo International
MTD
|
-127 M | $ 1 408.65 | 1.08 % | $ 29.9 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
NeoGenomics
NEO
|
902 M | $ 12.15 | 2.53 % | $ 1.54 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 6.84 | -0.36 % | $ 1.48 B | USA |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
261 M | $ 19.9 | -3.21 % | $ 1.07 B | USA |
 |
Pacific Biosciences of California
PACB
|
701 M | $ 2.12 | - | $ 538 M | USA |
 |
Celcuity
CELC
|
116 M | $ 101.74 | -3.33 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
18.9 M | $ 3.35 | -6.42 % | $ 107 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
12 B | $ 26.46 | -0.62 % | $ 20 B |  Niderland |
 |
Co-Diagnostics
CODX
|
86 M | $ 0.3 | -13.39 % | $ 8.8 M | USA |
 |
Precipio
PRPO
|
14.4 M | $ 24.67 | -1.2 % | $ 32 M | USA |
 |
Quidel Corporation
QDEL
|
11.9 B | $ 28.82 | 0.07 % | $ 1.21 B | USA |
 |
IQVIA Holdings
IQV
|
6.07 B | $ 224.13 | 0.84 % | $ 40.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | $ 45.14 | -0.21 % | $ 10 B | Niderland |
 |
Guardant Health
GH
|
-140 M | $ 103.55 | 1.45 % | $ 12.7 B | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
Sotera Health Company
SHC
|
405 M | $ 16.76 | -0.42 % | $ 4.74 B | USA |
 |
Soleno Therapeutics
SLNO
|
245 M | $ 49.79 | -4.25 % | $ 2 B | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Thermo Fisher Scientific
TMO
|
97.3 B | $ 574.27 | 0.46 % | $ 219 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 134.66 | -0.16 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
3.51 B | $ 197.59 | 2.36 % | $ 10.2 B | USA |
 |
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.96 | -10.6 % | $ 61.9 M |  Irlanda |
 |
Twist Bioscience Corporation
TWST
|
473 M | $ 31.39 | 1.47 % | $ 1.88 B | USA |
 |
Quotient Limited
QTNT
|
-35.6 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 184.04 | 0.81 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
20.9 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Myriad Genetics
MYGN
|
701 M | $ 7.07 | -2.01 % | $ 641 M | USA |